Nirmala Gonsalves, MD, discusses findings from the landmark DEGAS trial evaluating dupilumab in eosinophilic gastritis (EOG). She explores the evolving understanding of Type 2 inflammation, transcriptomic remodeling and the clinical implications of the trial results for gastroenterologists.
